Canadian Cannabis Market in Need of Standardization, Rigorous Testing
Original story from Delivra
Delivra has announced the publication of their analytical evaluation of a variety of third-party over-the-counter hemp consumer products for tetrahydrocannabinol (THC) and cannabidiol (CBD) content to further develop its internal expertise and evaluate the consumer landscape.
The publication conducted out of Delivra's research lab in Charlottetown, PEI and partially funded by Skills-PEI and by the Atlantic Canada Opportunities Agency, concluded that most third-party consumer products met the federal guidelines on THC content. However, the levels of CBD were higher than THC in multiple products and reflects the lack of federally mandated CBD testing of hemp-based finished products. As a tool, the testing method is amenable to a variety of consumer products indicating its general applicability towards cannabis oils and more complex materials like creams and edibles. Delivra is well positioned to be a preferred company of choice to provide the standardization of testing for the cannabis industry. These results have now been published in the respected peer-reviewed scientific journal, PLOS ONE, under the title, "A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products".
"This data underscores the variety of analytical expertise Delivra has developed in response to the intended legalization of cannabis-based products in Canada and is aligned with several active agreements between Delivra and third-party companies requesting our analytical and formulary expertise. Combining Delivra's unique knowledge of delivery systems with core analytical expertise prepares our company for further future opportunities in cannabis product development with a focus on safety and consistency," said Dr. Joseph Gabriele, CEO of Delivra.